Reduced Nocturnal Hypoglycemia with Basal Insulin Peglispro Compared to
Accepted Article
Insulin Glargine: Pooled Analyses of 5 Randomized Controlled Trials
AUTHORS: Julio Rosenstock1, Michel Marre2, Yongming Qu3, Shuyu Zhang3, Edward J. Bastyr III3,4, Melvin J. Prince3, Annette M. Chang3
AFFILIATIONS: 1Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA; 2Hopital Bichat Claude Bernard, Paris, France; 3Eli Lilly and Company,
Indianapolis, IN, USA; 4Indiana University School of Medicine, Indianapolis, IN, USA
CORRESPONDING AUTHOR: Annette M. Chang, Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. E-mail:
[email protected]
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.12757
This article is protected by copyright. All rights reserved.
Abstract Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action
Accepted Article
resulting from reduced peripheral effects. This report summarizes hypoglycemia data from five BIL Phase 3 studies with insulin glargine as comparator, including three double-blind trials. Pre-specified pooled analyses (n=4927) included: type 2 diabetes (T2D) basal only, T2D basal-bolus, and type 1 diabetes (T1D). BIL treatment resulted in 36-45% lower nocturnal hypoglycemia rate versus glargine despite greater reduction in HbA1c and higher basal insulin dosing. Total hypoglycemia rate was similar in T2D basal only, trended towards higher (10%) in T2D basal-bolus (p=0.053), and 15% higher (p
